Filing Details
- Accession Number:
- 0001193125-20-025229
- Form Type:
- 13G Filing
- Publication Date:
- 2020-02-05 14:13:34
- Filed By:
- Ubs Oncology Impact Fund L.p.
- Company:
- Viracta Therapeutics Inc. (NASDAQ:VIRX)
- Filing Date:
- 2020-02-05
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| UBS Oncology Impact Fund | 2,809,912 | 0 | 2,809,912 | 0 | 2,809,912 | 2.5% |
| Oncology Impact Fund (Cayman) Management | 2,809,912 | 0 | 2,809,912 | 0 | 2,809,912 | 2.5% |
| MPM Oncology Impact Management | 2,809,912 | 0 | 2,809,912 | 0 | 2,809,912 | 2.5% |
| MPM Oncology Impact Management GP | 2,809,912 | 0 | 2,809,912 | 0 | 2,809,912 | 2.5% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)*
Sunesis Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.0001
(Title of Class of Securities)
867328700
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Page 1 of 10
CUSIP No. 867328700
| 1. | Name of Reporting Persons
UBS Oncology Impact Fund L.P. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒1
| |||||
| 3. | SEC USE ONLY
| |||||
| 4. | Citizenship or Place of Organization
Cayman Islands | |||||
| Number of Owned by Person | 5. | Sole Voting Power
2,809,912 (See Items 2 and 4 herein) | ||||
| 6. | Shared Voting Power
0 | |||||
| 7. | Sole Dispositive Power
2,809,912(See Items 2 and 4 herein) | |||||
| 8. | Shared Dispositive Power
0 | |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,809,912 (See Items 2 and 4 herein) | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
| |||||
| 11. | Percent of Class Represented by Amount in Row (9)
2.5%* | |||||
| 12. | Type of Reporting Person (See Instructions)
PN | |||||
| * | This percentage is calculated based upon 111,320,000 outstanding shares of Common Stock of Sunesis Pharmaceuticals, Inc. (the Issuer), as reported on the Issuers most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the SEC) on November 12, 2019. |
| 1 | This Schedule 13G is being filed jointly by the Reporting Persons, as hereinafter defined. Such Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. |
Page 2 of 10
CUSIP No. 867328700
| 1. | Name of Reporting Persons
Oncology Impact Fund (Cayman) Management L.P. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒1
| |||||
| 3. | SEC USE ONLY
| |||||
| 4. | Citizenship or Place of Organization
Cayman Islands | |||||
| Number of Owned by Person | 5. | Sole Voting Power
2,809,912 (See Items 2 and 4 herein) | ||||
| 6. | Shared Voting Power
0 | |||||
| 7. | Sole Dispositive Power
2,809,912(See Items 2 and 4 herein) | |||||
| 8. | Shared Dispositive Power
0 | |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,809,912 (See Items 2 and 4 herein) | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
| |||||
| 11. | Percent of Class Represented by Amount in Row (9)
2.5%* | |||||
| 12. | Type of Reporting Person (See Instructions)
PN | |||||
| * | This percentage is calculated based upon 111,320,000 outstanding shares of Common Stock of Issuer, as reported on the Issuers most recent Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2019. |
| 1 | This Schedule 13G is being filed jointly by the Reporting Persons, as hereinafter defined. Such Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. |
Page 3 of 10
CUSIP No. 867328700
| 1. | Name of Reporting Persons
MPM Oncology Impact Management LP | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒1
| |||||
| 3. | SEC USE ONLY
| |||||
| 4. | Citizenship or Place of Organization
Delaware | |||||
| Number of Owned by Person | 5. | Sole Voting Power
2,809,912 (See Items 2 and 4 herein) | ||||
| 6. | Shared Voting Power
0 | |||||
| 7. | Sole Dispositive Power
2,809,912(See Items 2 and 4 herein) | |||||
| 8. | Shared Dispositive Power
0 | |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,809,912 (See Items 2 and 4 herein) | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
| |||||
| 11. | Percent of Class Represented by Amount in Row (9)
2.5%* | |||||
| 12. | Type of Reporting Person (See Instructions)
PN | |||||
| * | This percentage is calculated based upon 111,320,000 outstanding shares of Common Stock of Issuer, as reported on the Issuers most recent Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2019. |
| 1 | This Schedule 13G is being filed jointly by the Reporting Persons, as hereinafter defined. Such Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. |
Page 4 of 10
CUSIP No. 867328700
| 1. | Name of Reporting Persons
MPM Oncology Impact Management GP LLC | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒1
| |||||
| 3. | SEC USE ONLY
| |||||
| 4. | Citizenship or Place of Organization
Delaware | |||||
| Number of Owned by Person | 5. | Sole Voting Power
2,809,912 (See Items 2 and 4 herein) | ||||
| 6. | Shared Voting Power
0 | |||||
| 7. | Sole Dispositive Power
2,809,912(See Items 2 and 4 herein) | |||||
| 8. | Shared Dispositive Power
0 | |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,809,912 (See Items 2 and 4 herein) | |||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
| |||||
| 11. | Percent of Class Represented by Amount in Row (9)
2.5%* | |||||
| 12. | Type of Reporting Person (See Instructions)
OO | |||||
| * | This percentage is calculated based upon 111,320,000 outstanding shares of Common Stock of Issuer, as reported on the Issuers most recent Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2019. |
| 1 | This Schedule 13G is being filed jointly by the Reporting Persons, as hereinafter defined. Such Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. |
Page 5 of 10
| Item 1. |
|
| (a) | Name of Issuer |
Sunesis Pharmaceuticals, Inc.
| (b) | Address of Issuers Principal Executive Offices |
395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
| Item 2. |
|
| (a) | Name of Person Filing |
This Schedule 13G/A is being filed by UBS Oncology Impact Fund L.P. (UBS), Oncology Impact Fund (Cayman) Management, L.P. (OIF Cayman), MPM Oncology Impact Management, LP (MPM LP) and MPM Oncology Impact Management GP LLC (MPM GP, and together with UBS, OIF Cayman and MPM LP, the Reporting Persons).
| (b) | Address of Principal Business Office or, if none, Residence |
c/o MPM Capital LLC
450 Kendall Street
Cambridge, MA 02142
| (c) | Citizenship |
UBS and OIF Cayman are organized in the Cayman Islands and MPM LP and MPM GP are organized in Delaware.
| (d) | Title of Class of Securities |
Common Stock, par value $0.0001 per share (Common Stock)
| (e) | CUSIP Number |
867328700
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable
Page 6 of 10
| Item 4. | Ownership |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
| (a) | Amount beneficially owned: |
2,809,912 shares of Common Stock deemed beneficially owned by each of the Reporting Persons.
| (b) | Percent of class: |
2.5%, based upon 111,320,000 outstanding shares of the Issuers Common Stock, as reported on the Issuers most recent Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2019.
| (c) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote UBS has sole power to vote the 2,809,912 shares of Common Stock beneficially owned by UBS, and OIF Cayman, MPM LP, and MPM GP have sole power to direct the vote of the shares owned by UBS. |
| (ii) | Shared power to vote or to direct the vote None |
| (iii) | Sole power to dispose or to direct the disposition of UBS has sole power to dispose of the 2,809,912 shares of Common Stock beneficially owned by UBS, and OIF Cayman, MPM LP, and MPM GP have sole power to direct the disposition of the shares owned by UBS. |
| (iv) | Shared power to dispose or to direct the disposition of None |
OIF Cayman, as the general partner of UBS, MPM LP, as the general partner of OIF Cayman, and MPM GP, as the general partner of MPM LP, may be deemed to indirectly beneficially own the securities held by UBS. Ansbert Gadicke is the sole member of MPM GP. However, all voting and investment decisions are made by an investment committee comprised of three or more members, including Ansbert Gadicke. Each member of the investment committee expressly disclaims beneficial ownership of the reported securities.
Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that any such Reporting Person (other than UBS) is the beneficial owner of securities of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the Act), or for any other purpose (including, without limitation, any tax purposes) and each such Reporting Person expressly disclaims beneficial ownership of such securities. The filing of this statement should not be construed to be an admission that any member of the Reporting Persons are members of a group for the purposes of Section 13(d) and 13(g) of the Act.
| Item 5. | Ownership of Five Percent or Less of a Class |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
Not Applicable
Page 7 of 10
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. |
Not Applicable
| Item 8. | Identification and Classification of Members of the Group |
Not Applicable
| Item 9. | Notice of Dissolution of a Group |
Not Applicable
| Item 10. | Certification |
By signing below, each of the undersigned certifies that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
Page 8 of 10
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 4, 2020
| UBS ONCOLOGY IMPACT FUND L.P. | ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P. | |||||||
| By: | Oncology Impact Fund (Cayman) Management L.P, | By: | MPM Oncology Impact Management LP, | |||||
| its General Partner | its General Partner | |||||||
| By: | MPM Oncology Impact Management LP, | By: | MPM Oncology Impact Management GP LLC, | |||||
| its General Partner | its General Partner | |||||||
| By: | MPM Oncology Impact Management GP LLC, | By: | /s/ Ansbert Gadicke | |||||
| its General Partner | Name: Ansbert Gadicke | |||||||
| Title: Managing Member | ||||||||
| By: | /s/ Ansbert Gadicke | |||||||
| Name: Ansbert Gadicke | ||||||||
| Title: Managing Member | ||||||||
| MPM ONCOLOGY IMPACT MANAGEMENT LP | MPM ONCOLOGY IMPACT MANAGEMENT GP LLC | |||||||
|
By: |
MPM Oncology Impact Management GP LLC, | |||||||
| its General Partner | By: | /s/ Ansbert Gadicke | ||||||
| Name: Ansbert Gadicke | ||||||||
| By: | /s/ Ansbert Gadicke | Title: Managing Member | ||||||
| Name: Ansbert Gadicke | ||||||||
| Title: Managing Member | ||||||||
Exhibits
| A | Joint Filing Agreement |
Page 9 of 10